Biosimilar Glargine Insulin: Implications for Prescribers and Patients

被引：1
|
作者：
Pereira, Katherine [1 ,2 ]
机构：
[1] Duke Univ, Sch Nursing Durham, Durham, NC 27708 USA
[2] Duke Univ, Sch Nursing Durham, Doctor Nursing Practice Program, Div Endocrinol Metab & Nutr, Durham, NC 27708 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2017年 / 13卷 / 03期
关键词：
FOLLOW-ON-BIOLOGICS; COMPETITION;
D O I：
10.1016/j.nurpra.2016.11.022
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：236 / 237
页数：2
相关论文
共 50 条
  • [31] Insulin glargine versus NPH insulin in patients with type 1 diabetes
    Ratner, R
    DRUGS OF TODAY, 2003, 39 (11) : 867 - 876
  • [32] Comparative analysis of treatment outcomes of patients on insulin detemir and insulin glargine
    Alemayehu, B.
    Borah, B.
    Henk, H.
    Aagren, M.
    Forma, F.
    DIABETOLOGIA, 2008, 51 : S406 - S407
  • [33] Insulin glargine versus NPH insulin in critically ill medical patients
    Krumenacker, Laura
    Winters, Shauna
    Faircloth, Barbara
    McMillen, James
    Wylie, Doug
    Barlow, Patrick
    Ranganath, Harsha
    Branca, Paul
    CRITICAL CARE MEDICINE, 2013, 41 (12)
  • [34] Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to US- and EU-Licensed Insulin Glargine (IG)
    Heise, Tim
    Plum-Moerschel, Leona
    Andersen, Grit
    Lu, Jia
    Wilson, Michael G.
    Zijlstra, Eric
    DIABETES, 2021, 70
  • [35] Comparison of morning basal+1 bolus insulin therapy (insulin glulisine plus insulin glargine 300 U/mL vs insulin lispro plus insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
    Takeishi, Soichi
    Tsuboi, Hiroki
    Takekoshi, Shodo
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (01): : 91 - 99
  • [36] Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Proposed Biosimilar Insulin Glargine and Lantus® in Patients with Type 1 Diabetes (T1D)
    Heise, Tim
    Tagore, Ranitendranath
    Donnelly, Charles
    Barve, Abhijit
    Jacob, Anand
    DIABETES, 2017, 66 : A268 - A268
  • [37] Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Huster, W. J.
    Costigan, T. M.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    Konrad, R. J.
    DIABETOLOGIA, 2014, 57 : S397 - S398
  • [38] Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
    Li, Jing
    Ji, Jinzhi
    Liu, Fuyan
    Wang, Lingling
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (03) : 609 - 613
  • [39] ANALYSIS OF INSULIN GLARGINE IN THE TREATMENT OF ELDERLY PATIENTS WITH DIABETES
    Rubab, Aalia
    Zulfiqar, Zarmeena
    Rashid, Umar Hammad
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (06): : 12959 - 12961
  • [40] RISK OF HYPOGLYCEMIA WITH INSULIN GLARGINE IN CRITICALLY ILL PATIENTS
    Hite, Mindee
    Silinskie, Kevin
    CRITICAL CARE MEDICINE, 2009, 37 (12) : A112 - A112
12345